Related Experiment Video
Updated: May 23, 2026
Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
Published on: June 14, 2024
The three main stumbling blocks for anticancer T cells
Lukas Baitsch1, Silvia A Fuertes-Marraco, Amandine Legat
1Clinical Tumor Biology and Immunotherapy Unit, Ludwig Center for Cancer Research of the University of Lausanne, and Service of Radiation Oncology, Lausanne University Hospital Center, CH-1011 Lausanne, Switzerland.
Abstract:
Memory and effector T cells have the potential to counteract cancer progression, but often fail to control the disease, essentially because of three main stumbling blocks. First, clonal deletion leads to relatively low numbers or low-to-intermediate T cell receptor (TCR) affinity of self/tumor-specific T cells. Second, the poor innate immune stimulation by solid tumors is responsible for inefficient priming and boosting. Third, T cells are suppressed in the tumor microenvironment by inhibitory signals from other immune cells, stroma and tumor cells, which induces T cell exhaustion, as demonstrated in metastases of melanoma patients. State-of-the-art adoptive cell transfer and active immunotherapy can partially overcome the three stumbling blocks. The reversibility of T cell exhaustion and novel molecular insights provide the basis for further improvements of clinical immunotherapy.
Insights
T cells show promise against cancer but face hurdles like low affinity, poor immune stimulation, and T cell exhaustion. Overcoming these challenges through immunotherapy offers hope for better cancer treatment.
Area of Science:
- Immunology
- Oncology
- Cancer Immunotherapy
Background:
- Memory and effector T cells are crucial for controlling cancer.
- However, their effectiveness is limited by several key challenges in the tumor microenvironment.
- These limitations hinder the development of effective cancer immunotherapies.
Purpose of the Study:
- To identify and explain the primary obstacles preventing T cells from effectively combating cancer.
- To discuss current immunotherapy strategies that partially address these obstacles.
- To highlight the potential for future advancements in cancer immunotherapy.
Main Methods:
- Review of existing literature on T cell function in cancer.
- Analysis of the mechanisms behind T cell failure, including clonal deletion, immune stimulation, and T cell exhaustion.
- Evaluation of current adoptive cell transfer and active immunotherapy approaches.
Main Results:
- Three main barriers impede T cell anti-cancer activity: low T cell receptor (TCR) affinity, insufficient innate immune stimulation, and T cell suppression leading to exhaustion.
- Adoptive cell transfer and active immunotherapy can partially mitigate these issues.
- T cell exhaustion is reversible, offering a target for therapeutic improvement.
Conclusions:
- Understanding the barriers to T cell function is critical for improving cancer immunotherapy.
- Reversibility of T cell exhaustion and new molecular discoveries pave the way for enhanced clinical treatments.
- Further research into overcoming T cell suppression and enhancing immune stimulation is essential for advancing cancer immunotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:17The Tumor Microenvironment